EFFECT OF MOLSIDOMINE 16 MG ADMINISTERED ONCE-DAILY AS A LONG-TERM ADD-ON TREATMENT, ON ATHEROSCLEROSIS PROGRESSION AND INFLAMMATORY BIOMARKERS IN PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME. - PIMS (Plaque Imaging Molsidomine Study)
100 Clinical Results associated with Therabel Pharmaceuticals Ltd.
0 Patents (Medical) associated with Therabel Pharmaceuticals Ltd.
100 Deals associated with Therabel Pharmaceuticals Ltd.
100 Translational Medicine associated with Therabel Pharmaceuticals Ltd.